Abstract
Introduction
Photoselective vaporization of the prostate (PVP) has gained widespread acceptance as a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) [1] . In a meta-analysis of six randomized controlled trials comparing PVP with transurethral resection of the prostate (TURP), PVP was found to have comparable clinical outcomes, less blood loss, and shorter catheterization and hospitalization times than TURP [1] [2] [3] [4] [5] [6] [7] . Moreover, PVP is a viable option in elderly patients for whom TURP would be a risk [8] . The learning curve required to produce good clinical outcomes with PVP is short [9] . However, PVP does not enable diagnosis of incidental prostate cancer, as TURP can, because PVP does not provide prostate tissue for disease or greater. Conclusions: We found that it was possible to diagnose prostate cancer at a localized stage under our optimal PSA monitoring schedule before and after PVP.
Furusawa/Yamada/Soga/Kuromatsu pathological analysis. Additionally, PVP might mask the presence of prostate cancer and delay cancer diagnosis, and this delay could lead to cancer progression [10, 11] .
At our institution, we introduced PVP in April 2005 [12] . To prevent a delay in cancer diagnosis, we performed prostate biopsies for patients with a PSA level of 4.0 ng/ml or more before PVP. Then we carried out early monitoring for prostate cancer by measuring PSA levels regularly after PVP and assessed the clinical stages of prostate cancer diagnosed after PVP.
Materials and Methods
Patients (n = 800), who underwent PVP from April 2005 to December 2014 at our institution and were followed-up for more than 12 months, were analyzed retrospectively. The exclusion criteria for PVP were cases diagnosed with prostate cancer and no adaptation of anesthesia due to comorbidity. No size limitation existed.
We performed PVP for 450 patients using the 80 W GreenLight PV system (American Medical Systems, Minnetonka, MN, USA) from April 2005 to June 2011 and for 350 patients using the 120 W GreenLight HPS system from July 2011 to December 2014. The values of energy density (mean ± SD) were 5.4 ± 2.3 kJ/ml for all cases, 5.2 ± 2.4 kJ/ml for 80 W, and 5.7 ± 2.3 kJ/ml for 120 W, respectively.
Before PVP therapy, to rule out prostate cancer, serum PSA, digital examination, and transrectal ultrasound examination were performed. In cases in which the PSA was greater than 4 ng/ml or other suspicious findings were identified, transrectal prostatic biopsy was performed.
After PVP, PSA levels were measured at 3 and 12 months and then each year thereafter. We measured PSA levels at 3-6-month intervals when the PSA level did not decrease from baseline at Prostate Cancer Diagnosed after PVP 149 3 months or when the PSA level increased after a temporary decrease. Transrectal prostatic biopsy was performed when sequential PSA elevation at 3 points was observed from PSA nadir, without the cutoff criteria for PSA nadir.
We performed biopsies at 10 sites [8 sites in peripheral zone (PZ), 2 sites in transition zone (TZ)] by transrectal ultrasound for patients who had not undergone biopsy prior to PVP and at 12 sites (10 sites in PZ, 2 sites in TZ) for patients who had undergone prior biopsy. The clinical stages of prostate cancer were evaluated according to the Union for International Cancer Control TNM Classification of Malignant Tumors (7th edition, 2010). The risk classifications of prostate cancer were assessed with the D'Amico classification.
To compare postoperative PSA levels with baseline levels and the account of energy density in each case, the Wilcoxon test or unpaired t test were used, and statistical analysis were performed with R statistical programming software V 3.1.1 (R Project for Statistical Computing). Results with p values of less than 0.05 were considered significant.
Results
Baseline characteristics are listed in table 1. The numbers of evaluable patients and the percentage of the total at each point during follow-up are shown in figure 1. The mean follow-up period was 49 months (range 12-125 months). After PVP, 54 patients (6.8%) underwent prostate biopsies, and 23 (2.9%) patients were diagnosed with prostate cancer.
The mean PSA level of patients without prostate cancer decreased from baseline by 45% at 3 months and gradually increased over 5 years ( fig. 2) .
The values of energy density in cases with more than 50% reduction in PSA or without 50% reduction in PSA at 1 year after PVP were 5.6 ± 2.6 and 5.4 ± 2.3, respectively. Additionally, values of energy density in cases without more than 50% reduction in PSA tended to be lower than those of other cases, although the differences were not significant.
The PSA levels of patients diagnosed with prostate cancer showed a variety of changes ( fig. 3) .
For example, because all cases with PSA levels in the gray zone (4-10 ng/ml) underwent prostatic biopsy to exclude cases in which prostate cancer was present before PVP, these cases were candidates for treatment with PVP. Thus, 37.9% of cases (11/29), i.e., more than 1/4 of all cases, were categorized into the gray zone of PSA levels.
Also, the PSA levels of 4 patients did not decrease from baseline after PVP. In contrast, the PSA levels of 19 patients temporarily decreased from baseline at 3-6 months and then began to increase. Five patients were diagnosed with prostate cancer at PSA levels lower than the baseline.
The characteristics of the patients diagnosed with prostate cancer are listed in table 2. There were no cases in which the disease stage was greater than T2c or in which patients had metastasis. Initial treatments are listed in table 3. Within the observation period of an average of 35 months (range 2-92 months) after cancer diagnosis, no patients died of prostate cancer.
Discussion
PVP does not enable the diagnosis of incidental cancer, which can be diagnosed by TURP. Detection rates of incidental cancer after BPH surgery have decreased because of the introduction of PSA screening in the modern era. Tombal et al. [13] reported a decreased rate of incidental cancer after TURP and open enucleation from 27 to 9% when comparing their pre-PSA era and PSA era detection rates of incidental cancer. They found a larger decrease in T1b lesions, from 15 to 2%, than in T1a lesions, which stayed relatively constant (3-5%). Several studies have indicated that PSA screening decreases the detection rates of incidental cancer, specifically T1b lesions, and those data support the use of technologies, including PVP, which do not provide prostate tissue for pathological analysis [13] [14] [15] [16] .
However, PSA screening cannot prevent the occurrence of latent cancer. There is a possibility that prostate cancer may not be detected by PVP and can progress afterward. Thus, it is important for patients who undergo PVP to be monitored for prostate cancer. If clinically significant prostate cancer exists, PSA levels would be expected to increase continuously during follow-up. With regard to changes in PSA levels after PVP, Shim et al. [17] analyzed the PSA levels of 278 patients without prostate cancer who underwent PVP. They reported that the mean PSA level increased temporarily from baseline by 17% at 1 month and then began to decrease continuously afterward, showing decreases of 29 and 34% at 3 and 6 months, respectively, followed by stabilization between 6 and 12 months. Malek et al. [18] carried out a 5-year follow-up of 94 patients, who underwent PVP and found that the mean PSA level decreased from baseline by 33% at 3 months and by approximately 30% at 5 years. Five (5.0%) patients were diagnosed with localized prostate cancer during the follow-up. Lebdai et al. [19] assessed the PSA levels of 308 patients without prostate cancer who underwent PVP. They reported that the median PSA level decreased from baseline by 47% at 1 month, reached its nadir (52% reduction) at 6 months, and then exhibited a reduction of 44-52% from baseline at 4 years. They observed a slight re-increase in the median PSA level after its nadir. In our study, we also observed a re-increase in the mean PSA level after its nadir at 3 months. Although the reduction rates differ among reports, the mean PSA level after PVP was demonstrated to decrease after 1 month, reach its nadir at 3-6 months, and show stability or a slight re-increase thereafter [17] [18] [19] [20] [21] .
In terms of trends in PSA after PVP, the values of energy density affected PSA reduction. Indeed, higher energy density results in higher rates of PSA reduction [22] . According to our results, the values of energy density, in cases with more than 50% reduction in PSA, tended to be higher than those of other cases, although the differences were not significant. To predict trends in PSA after PVP, the energy density must be considered as a powerful factor.
However, PSA changes after PVP that predict prostate cancer have rarely been reported. The re-increase in PSA after PVP may be related to the regrowth of the remaining adenoma, excluding prostate cancer [19] . It is unknown which patients should undergo prostate biopsy when a continuous PSA increase is observed during follow-up. In the future, we must define optimal follow-up strategies to detect prostate cancer after PVP.
In this study, no cases of prostate cancer progressed rapidly just after the PVP procedure or were detected at an advanced stage. Marszalek et al. [23] reported functional outcomes and impact on survival of palliative TURP in 89 patients with prostate cancer. They demonstrated that the peri-operative mortality of palliative TURP was significantly higher (2%) than that for a contemporary series of BPH (< 0.25%) and also suggested the possibility of accelerating tumor growth by TURP [24] . Although a definitive conclusion has not been reached, it is possible that TURP may cause dissemination of prostate cancer cells into the circulation, which may lead to a more rapid progression of the disease [23, 25] . In contrast, Liberale et al. [26] presented their experience with PVP in 43 patients with prostate cancer and showed that for patients with prostate cancer, PVP is safe and provides excellent relief from symptoms. Altay et al. [27] compared PVP and TURP for bladder outlet obstruction by locally advanced (cT3/T4) prostate cancer. In their study, there were no significant differences in adverse events and primary functional outcomes between the 2 groups of 34 patients who underwent TURP and 35 patients who underwent PVP and completed 12 months of follow-up. A significant difference in catheter removal time (3.8 ± 11 vs. 1.2 ± 0.7 days, respectively) and hospital stay (2.9 ± 0.6 vs. 1.1 ± 0.5 days, respectively) was observed in favor of PVP. Metastatic disease developed in 5 (13.8%) patients in the TURP group but was not observed in the PVP group during the follow-up period. PVP has the advantages of less blood loss and lower risk of TURP syndrome and capsule perforation compared with TURP [1, 6] . Moreover, PVP provides adequate tissue vaporization and a coagulation effect without irrigant absorption [28] . These characteristics of PVP may allow prevention of tumor dissemination through cut veins, as with TURP [28] . Additionally, even if prostate cancer cannot be detected at the time of PVP, the possibility that PVP would cause dissemination of prostate cancer into the circulation and lead to more rapid progression of the disease remains low.
The major limitations of this study are the missing data and the short follow-up period. The dropout rates were 22% (175/782) at 24 months, 41% (178/433) at 60 months, and 78% (46/64) at 120 months. Thus, missing data could affect our results. The rate of patients with a follow-up period of less than 60 months was 68% (535/800).
Long-term follow-up is needed to confirm the rates of prostate cancer incidence and mortality in patients who undergo PVP.
In terms of screening for prostate cancer, our study contained insufficient information for evaluation of prostate cancer before PVP, because we excluded cases of prostatic cancer identified only by prostatic biopsy without MRI evaluation in several cases.
However, within the observation period for our patients who underwent PVP, no patients were diagnosed with advanced-stage prostate cancer or died of prostate cancer.
Conclusions
In terms of diagnostic screening for prostate cancer, the characteristic of PVP to provide no prostate tissue for pathological analysis was not a disadvantage, since our optimal PSA monitoring schedule could detect prostate cancer at the localized stage after PVP.
